Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Colchicine-Resistant Familial Mediterranean Fever
NCT01088880Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Familial Mediterranean fever (FMF), sponsored by Novartis. Primary endpoint: Percentage of patients with at least 50% reduction in FMF attack frequency at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT01088880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01088880.